Table 3.
Claims-based adherence/persistence results, during the maintenance period
| Measure | Total
|
RA/PA
|
IBD
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| SDM (n=94) |
Non-SDM (n=207) |
P-value | SDM (n=56) |
Non-SDM (n=111) |
P-value | SDM (n=30) |
Non-SDM (n=65) |
P-value | |
| MPR, during maintenance, mean (SD) | 0.91 (0.12) | 0.90 (0.14) | 0.511 | 0.90 (0.13) | 0.89 (0.15) | 0.733 | 0.92 (0.12) | 0.94 (0.08) | 0.344 |
| Persistence, days, mean (SD) | 111.2 (30.2) | 102.2 (38.1) | 0.029 | 109.6 (32.3) | 105.5 (36.8) | 0.477 | 113.5 (27.6) | 99.1 (36.7) | 0.060 |
| Cumulative time with refill gaps, days, mean (SD) | 17.8 (26.1) | 26.2 (33.2) | 0.018 | 20.5 (26.1) | 27.2 (32.4) | 0.184 | 12.6 (25.9) | 22.6 (33.7) | 0.153 |
Notes: Two aspects contributed to the lower n values for each group: patients whose index biologic was rituxan were excluded in calculations because this biologic is dosed as needed. Also, patients who discontinued or switched before the maintenance phase were excluded.
Abbreviations: IBD, inflammatory bowel disease; MPR, medication possession ratio; PA, psoriatic arthritis; RA, rheumatoid arthritis; SDM, shared decision-making; SD, standard deviation.